title: Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer.
abstract: Preliminary results of this ongoing phase II study of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus epirubicin administered as first-line treatment to women with metastatic breast cancer indicate encouraging response rates and no severe toxicity. Among the 57 patients admitted to this study, 52% had received prior adjuvant chemotherapy (85% with cyclophosphamide/methotrexate/5-fluorouracil), 46% had received radiotherapy, and 30% had received both forms of therapy; 63% of patients were postmenopausal, mainly with poorly differentiated tumors, and 80% presented with > or = 2 metastatic sites. Epirubicin 60 mg/m2 was administered intravenously as a 1-hour infusion followed by paclitaxel 175 mg/m2 infused over 3 hours. Standard premedication was given. Granulocyte colony-stimulating factor support was not used. Neutropenia was evident in 72% of cycles but was not severe. Instances of anemia and thrombocytopenia were rare. Alopecia was universal. All nonhematologic toxicity observed was mild or moderate (peripheral neuropathy, myalgia, nausea, vomiting World Health Organization toxicity grade < 2). At this time, 41 patients are currently evaluable for response, complete and partial remission are evident in seven and 21 patients, respectively. The overall response rate so far is 68%. An additional 12 patients show evidence of stable disease, and one has shown disease progression. Paclitaxel is considered a promising new drug in the adjuvant treatment of patients with metastatic breast cancer. Combining it with epirubicin allows safe administration with no evidence of severe cardiotoxicity. The incidence of adverse cardiac events was much lower than that observed with combinations of paclitaxel and doxorubicin.
authors.affiliation: Department of Obstetrics and Gynecology, Frauenklinik der Medizinischen Hochschule, Hannover, Germany.
authors.forename: H J
authors.initials: HJ
authors.lastname: Lück
authors.forename: C
authors.initials: C
authors.lastname: Thomssen
authors.forename: A
authors.initials: A
authors.lastname: du Bois
authors.forename: B W
authors.initials: BW
authors.lastname: Lisboa
authors.forename: M
authors.initials: M
authors.lastname: Untch
authors.forename: H
authors.initials: H
authors.lastname: Kühnle
authors.forename: F
authors.initials: F
authors.lastname: Jänicke
authors.forename: H G
authors.initials: HG
authors.lastname: Meerpohl
authors.forename: C
authors.initials: C
authors.lastname: Lindner
authors.forename: G
authors.initials: G
authors.lastname: Konecny
authors.forename: D
authors.initials: D
authors.lastname: Hecker
authors.forename: K
authors.initials: K
authors.lastname: Diergarten
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D015251:Epirubicin; D017239:Paclitaxel